Discovery - University of Dundee - Online Publications

Library & Learning Centre

Long-acting β-agonist prescribing in people with asthma in primary care

Standard

Long-acting β-agonist prescribing in people with asthma in primary care. / Morales, Daniel R; Jackson, Cathy; Fielding, Shona; Guthrie, Bruce.

In: Thorax, Vol. 68, No. 2, 01.02.2013, p. 192-194.

Research output: Contribution to journalArticle

Harvard

Morales, DR, Jackson, C, Fielding, S & Guthrie, B 2013, 'Long-acting β-agonist prescribing in people with asthma in primary care' Thorax, vol 68, no. 2, pp. 192-194. DOI: 10.1136/thoraxjnl-2012-202071

APA

Morales, D. R., Jackson, C., Fielding, S., & Guthrie, B. (2013). Long-acting β-agonist prescribing in people with asthma in primary care. Thorax, 68(2), 192-194. DOI: 10.1136/thoraxjnl-2012-202071

Vancouver

Morales DR, Jackson C, Fielding S, Guthrie B. Long-acting β-agonist prescribing in people with asthma in primary care. Thorax. 2013 Feb 1;68(2):192-194. Available from, DOI: 10.1136/thoraxjnl-2012-202071

Author

Morales, Daniel R; Jackson, Cathy; Fielding, Shona; Guthrie, Bruce / Long-acting β-agonist prescribing in people with asthma in primary care.

In: Thorax, Vol. 68, No. 2, 01.02.2013, p. 192-194.

Research output: Contribution to journalArticle

Bibtex - Download

@article{2c45d39c61804a84a9270104f9434430,
title = "Long-acting β-agonist prescribing in people with asthma in primary care",
author = "Morales, {Daniel R} and Cathy Jackson and Shona Fielding and Bruce Guthrie",
note = "Copyright 2013 Elsevier B.V., All rights reserved.",
year = "2013",
month = "2",
doi = "10.1136/thoraxjnl-2012-202071",
volume = "68",
pages = "192--194",
journal = "Thorax",
issn = "0040-6376",
number = "2",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Long-acting β-agonist prescribing in people with asthma in primary care

AU - Morales,Daniel R

AU - Jackson,Cathy

AU - Fielding,Shona

AU - Guthrie,Bruce

N1 - Copyright 2013 Elsevier B.V., All rights reserved.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Long-acting ß2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

AB - Long-acting ß2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

UR - http://www.scopus.com/inward/record.url?scp=84872686039&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2012-202071

DO - 10.1136/thoraxjnl-2012-202071

M3 - Article

VL - 68

SP - 192

EP - 194

JO - Thorax

T2 - Thorax

JF - Thorax

SN - 0040-6376

IS - 2

ER -

Documents

DOI

Library & Learning Centre

Contact | Accessibility | Policy